EKRA Compliance in Alabama Toxicology Networks: What the National Fraud Takedown Means for SUD Lab Referrals

Healthcare fraud enforcement continues to place laboratory testing, referral arrangements, and billing practices under close scrutiny. For Alabama laboratories serving substance use disorder (SUD) treatment providers, the issue is especially relevant when toxicology testing is connected to referral relationships or financial arrangements.

The Eliminating Kickbacks in Recovery Act (EKRA) is one federal law that laboratories and treatment organizations need to understand. Enacted in 2018, EKRA addresses certain payments and other forms of remuneration connected to referrals involving laboratories, recovery homes, and clinical treatment facilities.

The law can apply to services covered by both government and private health benefit programs. As a result, commercial insurance does not automatically remove EKRA considerations from a laboratory arrangement.

Understanding EKRA and Laboratory Referrals

EKRA generally prohibits knowingly and willfully offering, paying, soliciting, or receiving remuneration to induce or reward referrals to a laboratory, recovery home, or clinical treatment facility, subject to statutory exceptions.

For toxicology laboratories, the concern often centers on how referrals are generated and how individuals involved in those referrals are compensated.

A laboratory may work with treatment centers, healthcare providers, marketing organizations, sales representatives, or independent contractors. These relationships are not inherently unlawful. The compliance question depends on the actual structure of the arrangement, including what services are provided, how compensation is calculated, and whether financial benefits are connected to referrals or laboratory business.

This makes it important to evaluate the substance of a business relationship rather than relying solely on the title of a contract.

Why Toxicology Testing Deserves Particular Attention

Toxicology testing can be part of clinical management for patients receiving SUD treatment. Depending on the patient's circumstances, testing may provide information that helps a clinician monitor treatment and make clinical decisions.

At the same time, laboratory testing creates a billing event. When testing occurs repeatedly across a large patient population, financial incentives can become significant.

That is why referral arrangements should be considered alongside laboratory utilization and billing practices. A compliance review should examine whether testing decisions are clinically appropriate, properly documented, accurately coded, and billed according to applicable payer requirements.

The financial relationship surrounding a referral should also be examined independently from the clinical decision to order a test.

Compensation Structures Can Create Risk

Compensation is one of the most important areas for laboratories to review.

EKRA contains an exception addressing certain payments made by employers to employees or independent contractors, but the statutory language places restrictions on compensation determined by or varied according to factors such as referrals, the number of procedures performed, or amounts billed or received for referred individuals.

That means laboratories should pay close attention to compensation models involving sales representatives, marketers, consultants, and other referral-related personnel.

A payment described as a marketing fee does not automatically resolve the issue. What matters is how the arrangement operates in practice.

For example, an arrangement that pays a fixed amount for legitimate administrative or marketing work presents a different set of questions from one in which compensation increases directly with laboratory referrals or testing volume. Specific arrangements should be reviewed based on their facts and applicable legal requirements.

Commercial Insurance Does Not Eliminate EKRA Concerns

EKRA is particularly important because its scope is not limited to federal healthcare programs in the same way as the federal Anti-Kickback Statute.

The statute addresses remuneration connected with services covered by a health benefit program, a concept that includes private health plans. Therefore, a toxicology laboratory should not assume that an arrangement is outside EKRA simply because the laboratory primarily serves commercially insured patients.

This distinction matters for Alabama SUD networks where patients may have a mixture of Medicaid, Medicare, employer-sponsored, and other commercial coverage.

Each arrangement should be evaluated according to the applicable laws, payer requirements, and specific facts.

What the National Fraud Takedown Means for Alabama Labs

The 2026 National Health Care Fraud Takedown involved hundreds of defendants and billions of dollars in alleged fraudulent healthcare claims. Federal and state agencies, including Medicaid Fraud Control Units, participated in the coordinated enforcement effort.

The Alabama case included in the federal case summaries involved alleged false Medicaid billing by a healthcare provider. It was not identified by the Department of Justice as an EKRA toxicology referral prosecution.

That distinction is important. The national operation does not establish that Alabama toxicology laboratories or SUD treatment organizations as a group are engaging in unlawful conduct.

It does, however, illustrate the broader enforcement environment surrounding healthcare billing and fraud.

Laboratories operating within SUD networks can use this environment as an opportunity to examine referral arrangements, compensation structures, documentation, and billing controls before potential issues become larger compliance problems.

Connecting EKRA Compliance With Laboratory Billing

Referral compliance should not be separated from laboratory billing operations.

A toxicology claim typically involves several stages: a patient receives a clinical evaluation, a provider determines whether testing is appropriate, an order is placed, a specimen is collected, testing is performed, results are reported, and a claim is submitted.

Each stage should be supported by appropriate documentation.

Accurate coding is also important because laboratory services can involve specific coding and payer requirements. Organizations reviewing their testing operations may therefore benefit from examining their laboratory billing and coding services alongside their broader compliance processes.

The goal is not simply to submit a technically correct claim. The billing record should accurately represent the service that was ordered, performed, documented, and reported.

Reviewing Toxicology Referral Relationships

An Alabama laboratory can begin a compliance review by identifying every organization and individual involved in generating laboratory business.

This may include SUD treatment facilities, healthcare providers, marketing companies, sales representatives, management organizations, and independent contractors.

The laboratory should then examine how each relationship works in practice. Who selects the laboratory? Who communicates with referring providers? How is each party compensated? Does compensation change based on referrals, specimens, tests, or revenue?

These questions can help identify arrangements that deserve further legal review.

It is also important to compare written contracts with actual business practices. A contract may describe a relationship as general marketing or consulting, while the real-world activities may involve directing patients or providers toward a particular laboratory.

Keeping Clinical Decisions Independent

A sound compliance framework separates financial incentives from clinical decision-making.

The need for toxicology testing should be determined by the patient's clinical circumstances and the treating provider's professional judgment. Laboratory selection should likewise follow applicable requirements rather than being driven by an improper financial incentive.

For laboratories, this means maintaining clear policies around referrals, ordering, marketing, compensation, documentation, and billing.

Internal monitoring can also help identify unusual testing or referral patterns. Significant changes in volume, unusually concentrated referrals, or compensation that closely tracks laboratory revenue may warrant additional review.

Why Ongoing Review Matters

EKRA compliance (https://translabsbilling.com/blog/ekra-compliance-in-alabama/) is not necessarily a one-time exercise.

Laboratory relationships can change as new providers join a network, contracts are modified, payer participation expands, or marketing arrangements evolve. A compensation structure that was created for one purpose may operate differently after a business relationship expands.

Periodic review allows laboratories and SUD organizations to identify these changes and determine whether existing arrangements still meet applicable requirements.

For more specialized laboratory operations, reviewing Lab billing and coding (https://translabsbilling.com/service/laboratory-billing-and-coding-services/) can also help organizations examine whether their testing claims, coding practices, and payer requirements are being handled consistently.

A More Careful Approach to SUD Laboratory Referrals

The current enforcement environment does not mean every referral relationship should be viewed as suspicious. It does mean that laboratories have good reason to understand their financial and operational relationships in detail.

For Alabama toxicology networks, the practical focus should be on how referrals are generated, how compensation is determined, whether clinical decisions remain independent, and whether laboratory services are accurately documented and billed.

EKRA should also be considered alongside the federal Anti-Kickback Statute, False Claims Act, applicable state requirements, and payer rules. Because EKRA is a federal criminal statute, laboratories and treatment organizations evaluating specific arrangements should seek advice from qualified healthcare regulatory counsel.

A careful approach to referral relationships, documentation, compensation, and laboratory billing can help organizations identify potential compliance issues before they develop into more serious problems.